Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL
0 Lượt xem
• 07/14/23
0
0
Nhúng
administrator
Người đăng ký
In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…
Cho xem nhiều hơn
Bình luận trên Facebook
SORT BY-
Nhận xét hàng đầu
-
Bình luận mới nhất